Why is "Irinotecan" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-18 04:39:38
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Irinotecan entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-18 and was most recently seen on 2026-07-18.
Wikipedia Overview
Irinotecan, sold under the brand name Camptosar among others, is an anti-cancer medication used to treat colon cancer and small cell lung cancer. For colon cancer it is used either alone or with fluorouracil. For small cell lung cancer it is used with cisplatin. It is given intravenously.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Irinotecan: Mechanism of Action, Dose, Administration, Clinical Uses, and Side Effects - Oncodaily
-
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial - Nature
-
Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy - The ASCO Post
-
FDA Grants Orphan Drug Designation to Irinotecan Delivery Implant for High-Grade Glioma - Targeted Oncology
-
FDA Grants Orphan Drug Status to Irinotecan-ChemoSeed for Malignant Glioma - cancernetwork.com
-
Irinotecan-induced neutropenia: A comprehensive review of pathogenesis, risk factors, and management - EurekAlert!
-
O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation-Guided Irinotecan-Based Therapy in Metastatic Colorectal Cancer: A Case Report - Cureus
-
Neoadjuvant FOLFIRINOX Therapy for a Patient with Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Hemodialysis: Case Report - Journal of Hematology Oncology Pharmacy
-
A case report of advanced pancreatic cancer patient demonstrating remarkable efficacy with liposomal irinotecan after failure of multiple-line therapies - Frontiers
-
Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study - Nature
-
A Multicenter Single-Arm Phase II Trial Evaluating the Safety and Efficacy of Panitumumab and Irinotecan in Patients with NeoRAS Wild-Type Metastatic Colorectal Cancer (C-PROWESS Trial) - EMJ
-
Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma - ESMO Daily Reporter
-
Intensified Pre-Op Chemoradiotherapy Fails in Locally Advanced Rectal Cancer - MedPage Today
-
Scientists Found 2 Existing Drugs Could Reverse Alzheimer's Brain Damage in Mice - ScienceAlert
-
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, 5-Fluorouracil Found to Be Effective in Previously Untreated, Locally Advanced Pancreatic Carcinoma - ASCO Daily News
-
Lurbinectedin Misses Survival End Point in Second-Line SCLC Trial - cancernetwork.com
-
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma - Targeted Oncology
-
Thapsigargin enhanced chemotherapeutic sensitivity of irinotecan in the inflammation-induced colorectal cancer model in mice | Scientific Reports - Nature
-
LyRiCX Trial Results at ASCO GI 2026: Liposomal irinotecan, carboplatin or oxaliplatin with or without Nivolumab in the 1L treatment of Metastatic Esophagogastric Adenocarcinoma - Oncodaily
-
Ivonescimab Combo Yields Encouraging Activity in Previously Treated SCLC - cancernetwork.com
-
Topline LAGOON Results Show Missed OS End Point With Lurbinectedin in Relapsed SCLC - OncLive
-
FDA Grants Fast Track to Alnodesertib Combo for Metastatic Colorectal Cancer - Targeted Oncology
-
AI Helps Tailor Better Therapy for Bowel Cancer - Inside Precision Medicine
-
FDA Grants Fast Track Designation to Alnodesertib Plus Irinotecan in ATM-Negative mCRC - OncLive
-
Pancreatic cancer: UGT1A1 status did not stratify outcomes with liposomal irinotecan regimens - Vera Health
-
Oncology Drugs Fast-Tracked by the FDA in November 2025 - Oncology News Central
-
Ewing Sarcoma’s EWS::FLI1 Trial Just Showed What Precision Oncology Has Been Promising for a Decade - The Clinical Trial Vanguard
-
FDA Fast Track Designation Granted to Alnodesertib Plus Irinotecan for ATM-Negative Third-Line Metastatic Colorectal Cancer - Vera Health
-
AI Reveals Cancer Therapy’s Effectiveness - Technology Networks
-
Platinum-sensitive relapsed ES-SCLC: Liposomal irinotecan plus platinum shows early response signal - Vera Health
-
Ozekibart/FOLFIRI Yield Activity in Pretreated Advanced Colorectal Cancer - cancernetwork.com
-
Butyrate prevents chemotherapy-induced gastrointestinal toxicity and microbial dysbiosis - Nature
-
Onivyde® improves survival in Phase III pancreatic cancer trial - European Pharmaceutical Review
-
New Nanomedicine Approach Boosts Chemotherapy And Immune Activity In Pancreatic Cancer - AZoNano
-
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study - Nature
-
Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair - Nature
-
The effective combination therapies with irinotecan for colorectal cancer - Frontiers
-
Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study - Nature
-
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, rand - The Lancet
-
Chemotherapy-Induced Diarrhea: Mechanisms, Risk Factors, Impact, and Management - Oncodaily
-
Liposomal Irinotecan in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma - The ASCO Post
-
Alnodesertib Receives FDA Fast Track Designation For ATM– Metastatic CRC - cancernetwork.com
-
Irinotecan: 25 years of cancer treatment - ScienceDirect.com
-
A promising new treatment strategy for hepatoblastoma - Drug Target Review
-
NALIRIFOX Remains Effective Despite Dose Modification in First-Line PDAC - OncLive
-
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel - Nature
-
Chemotherapy-Induced Diarrhea: Options for Treatment and Prevention - Journal of Hematology Oncology Pharmacy
-
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer - Nature
-
Dr Wainberg on Selecting Between FOLFIRINOX and NALIRIFOX in Frontline Pancreatic Cancer - OncLive
-
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial - Nature
-
Lower Liposomal Irinotecan/Oxaliplatin Doses Do Not Worsen PDAC Outcomes - cancernetwork.com
-
Liposomal Irinotecan Is Active After Prior Treatment in Pancreatic Cancer - Targeted Oncology
-
FDA Approves Irinotecan Liposome to Treat Pancreatic Cancer - cancer.gov
-
Alnodesertib Wins FDA Fast Track Status in ATM-Negative Colorectal Cancer - Cure Today
-
Novel Computational Approach Identifies Cancer Drug Combo That Could Treat Alzheimer's Disease - Neurology Today
-
Irinotecan-Induced Transient Dysarthria in a Patient With Metastatic Colorectal Cancer: A Case Report - Cureus
-
Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer - The ASCO Post
-
Study identifies PARG as a new target to enhance chemotherapy in colorectal cancer - EurekAlert!
-
Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study - Nature
-
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301) - Nature
-
Russian scientists develop method for safer cancer drugs - Новости GxP
-
Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system - Nature
-
Ramucirumab Beyond Progression Plus Irinotecan in Ramucirumab-Refractory Advanced Gastric Cancer - The ASCO Post
-
Korea clears Onconic’s nesuparib for late-line metastatic gastric cancer trial - Korea Biomedical Review
-
Personal Experience With Liposomal Irinotecan - OncLive
-
Contribution of HIF-1α/BNIP3-mediated autophagy to lipid accumulation during irinotecan-induced liver injury - Nature
-
Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis - Frontiers
-
Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC - Nature
-
Liposomal Irinotecan for Pancreatic Cancer: Is It Worth It? - Medscape
-
Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11) - PNAS
-
ITMO Researchers Find New Molecular Target for Popular Cancer Treatment - Университет ИТМО
-
Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients - Nature
-
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort - Nature
-
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status - ASCO Publications
-
Dose Reductions of Liposomal Irinotecan, Oxaliplatin Don’t Affect OS in Metastatic PDAC - Targeted Oncology
-
Responses to Irinotecan, Temozolomide, Dinutuximab, and GM-CSF Regimen in Patients With Relapsed High-Risk Neuroblastoma - The ASCO Post
-
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial - Nature
-
Phase II Study of NALIRIFOX in Locally Advanced Pancreatic Carcinoma (LAPC) Shows Durable Disease Control and Improved Quality of Life - Oncodaily
-
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin - Nature
-
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy - Nature
-
Nanoliposomal Irinotecan's Role in Pancreatic Cancer - OncLive
-
High‐Load Core@Shell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer - Notter - 2024 - Small Science - Wiley Online Library
-
AI Identifies Cancer Patients for Targeted Treatment - The Engineer
-
Randomized Phase III trial of Ramucirumab finds benefit for patients with refractory advanced gastric cancer - 2 Minute Medicine
-
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma - Wiley & Sons
-
FDA Grants Fast Track Status to Irinotecan Liposome Injection for Second-Line SCLC - OncLive
-
Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer - RSNA Journals
-
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma - Nature
-
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial | British Journal of Cancer - Nature
-
FDA Approves Irinotecan Liposome Combo in Metastatic Pancreatic Cancer - Oncology News Central
-
No OS Benefit With Ramucirumab Plus Irinotecan in Gastric/GEJ Cancer - Cancer Therapy Advisor
-
Nanoliposomal Irinotecan Fails to Boost Survival in Treated Advanced Biliary Cancer - MedPage Today
-
KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer - Wiley & Sons
-
Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC - cancernetwork.com
-
Irinotecan Liposome Injection Plus NALIRIFOX Meets Primary End Point for Most Common Type of Pancreatic Cancer - cancernetwork.com
-
Fluorouracil, leucovorin and irinotecan plus panitumumab for the treatment of metastatic colorectal cancer - physiciansweekly.com
-
Vincristine/Irinotecan Plus Temozolomide Shows Improved Efficacy in Relapsed/Refractory Rhabdomyosarcoma - cancernetwork.com
-
Convection-Enhanced Delivery of Nanoliposomal Irinotecan for Recurrent Glioblastoma or High-Grade Glioma - Targeted Oncology
-
Liposomal Irinotecan Plus 5-FU/LV Improves Survival Outcomes in Biliary Tract Cancer - cancernetwork.com
-
A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.